A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy (1943)
Danielle Brander
2019 Presentations Access
Thank you for your interest in viewing the iwCLL 2019 video presentations.
Please complete the following information below to access the presentations.
